United Therapeutics UTHR Cash ratio
Cash ratio at other companies
Other financials
Where this comes from
Calculated from United Therapeutics’s reported figures.
Based on the most recent quarter.
The official record: United Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about United Therapeutics's cash ratio.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is United Therapeutics's cash ratio?
- United Therapeutics (UTHR) reported cash ratio of 2.1× in Q1 2026.
- How has United Therapeutics's cash ratio changed year-over-year?
- United Therapeutics's cash ratio decreased by 18.9% year-over-year, from 2.6× to 2.1×.
- What is the long-term trend for United Therapeutics's cash ratio?
- Over 4 years (2021 to 2025), United Therapeutics's cash ratio has grown at a -1.5% compound annual growth rate (CAGR), from 11.5× to 10.9×.
- What does cash ratio mean?
- How much of its short-term bills the company could pay with cash on hand right now.
- How do you interpret cash ratio?
- A buffer against stress, but persistently high cash ratios can indicate under-deployed capital. Interpret alongside the company's capital-allocation strategy.
- How does cash ratio compare across companies?
- Varies widely by business model and treasury policy; best read against the company's own history.